市场调查报告书
商品编码
1500547
转染技术市场:按产品、方法、技术、应用和最终用户划分 - 2024-2030 年全球预测Transfection Technologies Market by Product (Instrument, Reagent & Kits), Method (Cationic Lipid Transfection, Cotransfection, Electroporation), Technology, Applications, End-user - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年转染技术市场规模为12.2亿美元,预计2024年将达13.5亿美元,2030年将达23.9亿美元,复合年增长率为9.97%。
转染技术将外源核酸引入细胞并产生基因改造细胞。它在分子生物学研究、基因治疗和重组蛋白药物开发中至关重要。转染技术的不断创新提供了更高的效率和更低的细胞毒性,正在推动市场成长。政府和私人组织增加研发资金,以及扩大基因组和基因编辑研究,也对市场环境产生正面影响。然而,先进转染技术及相关产品的高成本限制了转染技术解决方案的取得。对基因治疗产品的严格监管要求可能会阻碍开发进度。此外,日益关注提高转染效率和最小化细胞毒性效应可能是一个重要的潜在机会领域。开拓新型非病毒递送系统和扩大商业性治疗应用的製程也是市场成长的有希望的因素。
主要市场统计 | |
---|---|
基准年[2023] | 12.2亿美元 |
预测年份 [2024] | 13.5亿美元 |
预测年份 [2030] | 23.9亿美元 |
复合年增长率(%) | 9.97% |
区域洞察
在美洲,美国和加拿大由于在生物技术和药物研究方面的大量投资,在全球转染技术市场中占据重要地位。重要的生物技术公司的存在、强大的智慧财产权保护框架以及重大的研究倡议都强调了该地区对创新的承诺。最近关于非病毒基因转移系统的专利反映了人们对提高转染效率和安全性的持续关注。由于成员国之间的监管和资金筹措情况不同,欧盟 (EU) 的市场格局十分复杂。然而,欧盟范围内促进基因组学和个人化医疗研究的努力正在推动对先进转染解决方案的需求,特别是对将这些技术纳入治疗开发平臺。中东和非洲 (MEA) 是一个新兴但快速成长的市场。对医疗保健基础设施的投资和对生物医学研究伙伴关係的更多关注是中东和非洲地区的主要趋势。在中国、日本和印度等国家的推动下,亚太地区的转染技术市场正在快速成长。对生物技术和医疗保健研究的大量投资、政府对基因组计划的支持以及对个人化医疗日益增长的兴趣正在推动亚太地区的成长。在基因治疗和再生医学研究的推动下,非病毒转染方法的需求特别高。
FPNV定位矩阵
FPNV定位矩阵对于评估供应商在转染技术市场的定位至关重要。此矩阵提供了对供应商的全面评估,并检查了与业务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果,供应商被分为代表其成功程度的四个像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对转染技术市场中供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献,您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外,该分析还提供了对该行业竞争性质的宝贵见解,包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息,供应商可以做出更明智的决策并製定有效的策略,以在市场竞争中保持领先地位。
策略分析与建议
策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在转染技术市场中的地位进行全面评估,使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析,以确定核心优势和需要改进的领域。
[193 Pages Report] The Transfection Technologies Market size was estimated at USD 1.22 billion in 2023 and expected to reach USD 1.35 billion in 2024, at a CAGR 9.97% to reach USD 2.39 billion by 2030.
Transfection technologies involve the introduction of foreign nucleic acids into cells to produce genetically modified cells. Transfection technologies are crucial in molecular biology research, gene therapy, and the development of recombinant protein drugs. Ongoing innovations in transfection techniques that offer higher efficiency and lower cytotoxicity are driving the market growth. Increased funding in R&D by governments and private entities and expansion in genomics and gene editing research is also positively influencing the market landscape. However, the high cost of advanced transfection technologies and related products limits the accessibility of transfection technology solutions. Stringent regulatory requirements for gene therapy products can impede development timelines. Moreover, Increased focus on enhancing transfection efficiency and minimizing the cytotoxic effects can serve as significant areas for potential opportunities. Developing novel, non-viral delivery systems and scaling up processes for commercial therapeutic applications are also promising for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 1.22 billion |
Estimated Year [2024] | USD 1.35 billion |
Forecast Year [2030] | USD 2.39 billion |
CAGR (%) | 9.97% |
Regional Insights
In the Americas, the United States and Canada hold a significant position in the global transfection technologies market, driven by substantial investments in biotechnology and pharmaceutical research. The presence of crucial biotech firms, a robust framework for intellectual property protection, and significant research initiatives underscore the commitment to innovation in the Americas region. Recent patents in non-viral gene delivery systems reflect the ongoing focus on improving transfection efficiency and safety. In the European Union, diverse regulatory and funding landscapes across member states create a complex market for transfection technologies. However, EU-wide initiatives to promote research in genomics and personalized medicine are driving demand for advanced transfection solutions, with particular interest in integrating these technologies into therapeutic development pipelines. The Middle East and Africa (MEA) present a nascent but rapidly growing market for transfection technologies. Investments in healthcare infrastructure and a growing focus on biomedical research partnerships are key trends in the MEA region. The Asia Pacific region, led by countries such as China, Japan, and India, is witnessing rapid growth in the transfection technologies market. Heavy investments in biotechnology and healthcare research, government support for genomics projects, and a growing emphasis on personalized medicine propel the growth in the APAC region. The demand for non-viral transfection methods is particularly high, driven by gene therapy and regenerative medicine research.
Market Insights
The market dynamics represent an ever-changing landscape of the Transfection Technologies Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Transfection Technologies Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Transfection Technologies Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Polyplus Launches FectoVIR-LV Transfection Reagent with New DOE Service Options
Polyplus, a subsidiary of Satorius, launched FectoVIR-LV, a groundbreaking transfection reagent specifically designed to enhance lentiviral vector (LV) production for gene-modified cell therapies including CAR-T and stem cell treatments. Recognizing the escalating demand for LVs as these therapies evolve, Polyplus offers a solution that addresses the critical need for scalability in production without compromising time or cost efficiency. FectoVIR-LV distinguishes itself by being animal component-free and optimized for scaling up in suspension HEK-293 cell systems, significantly improving LV yield and stability. [Published On: 2023-08-29]
BioCentriq and Kytopen Expand Partnership to Expedite Impact of Transformative Gene-Editing Technology on Cell Therapy Manufacturing
BioCentriq,has significantly enhanced its partnership with Kytopen, a cutting-edge startup emanating from MIT, aimed at revolutionizing transfection technologies. This partnership, has successively moved beyond its preliminary phase, wherein the combined efforts of BioCentriq and Kytopen meticulously evaluated the use of Kytopen's state-of-the-art Flowfect technology for T-cell transfection. [Published On: 2023-06-06]
Avectas Launches the Solupore Platform for the Clinical Manufacturing of Next- Generation Gene-Modified Cell Therapies with Unparalleled Cell Health and Functionality
Avectas launched its pioneering Solupore platform during Advanced Therapies Week at the Miami Beach Convention Centre. Engineered to revolutionize cell therapy manufacturing, the Solupore system stands out for its non-viral, membrane-permeabilizing methodology, ensuring the delivery of various molecular cargoes-including mRNA, plasmids, RNP, and CRISPR/Cas9-while maintaining optimal cell health and functionality. This advancement opens new avenues for complex genetic editing and the delivery of challenging materials. [Published On: 2023-01-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Transfection Technologies Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Transfection Technologies Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., Akron Biotech, Altogen Biosystems, Bio-Rad Laboratories, Inc., Biomol GmbH, Epoch Life Science, F. Hoffmann-La Roche AG, FUJIFILM Wako Pure Chemical Corporation, Geno Technology, Inc., Lonza Group, Maxcyte Inc., Merck KGaA, Mirus Bio, OriGene Technologies, Inc., OZ Biosciences SAS, Polyplus-transfection SA by Sartorius AG, Polysciences, Inc., Promega Corporation, Qiagen NV, Reprocell Inc., SignaGen Laboratories, Takara Bio Inc., Thermo Fisher Scientific, Inc., and VWR International, LLC by Avantor.
Market Segmentation & Coverage